{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:26:51Z","timestamp":1778261211131,"version":"3.51.4"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"DOI":"10.1007\/s12031-025-02462-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:41:50Z","timestamp":1770273710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cUnfolding Parkinson\u2019s Disease Through the Microbiome-Gut-Brain Axis\u201d"],"prefix":"10.1007","volume":"76","author":[{"given":"Ramana Kamatchi","family":"Shenthilvel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thangavelu Arumugam","family":"Umashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deenathayalan","family":"Uvarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohana","family":"Mathuraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Ravikumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"3","key":"2462_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1212\/WNL.57.3.456","volume":"57","author":"RD Abbott","year":"2001","unstructured":"Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson\u2019s disease. Neurology 57(3):456\u2013462. https:\/\/doi.org\/10.1212\/WNL.57.3.456","journal-title":"Neurology"},{"issue":"12","key":"2462_CR2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/ph15121554","volume":"15","author":"K Abu-Elfotuh","year":"2022","unstructured":"Abu-Elfotuh K, Hamdan AME, Mohammed AA, Atwa AM, Kozman MR, Ibrahim AM, Motawea SM, Selim HMRM, Tohamy STK, El-Din MN, Zaghlool SS, Gowifel AMH, Awny MM (2022) Neuroprotective effects of some nutraceuticals against manganese-induced Parkinson\u2019s disease in rats: possible modulatory effects on TLR4\/NLRP3\/NF-\u03baB, GSK-3\u03b2, Nrf2\/HO-1, and apoptotic pathways. Pharmaceuticals 15(12):1554. https:\/\/doi.org\/10.3390\/ph15121554","journal-title":"Pharmaceuticals"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/bs.ant.2024.02.003","volume":"11","author":"IA Adedara","year":"2024","unstructured":"Adedara IA, Mohammed KA, Canzian J, Ajayi BO, Farombi EO, Emanuelli T, Rosemberg DB, Aschner M (2024) Utility of zebrafish-based models in understanding molecular mechanisms of neurotoxicity mediated by the gut-brain axis. Adv Neurotoxicol 11:177\u2013208. https:\/\/doi.org\/10.1016\/bs.ant.2024.02.003","journal-title":"Adv Neurotoxicol"},{"issue":"1","key":"2462_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1021\/acs.chemrev.2c00431","volume":"123","author":"N Aggarwal","year":"2023","unstructured":"Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW (2023) Microbiome and human health: current understanding, engineering, and enabling technologies. Chem Rev 123(1):31\u201372. https:\/\/doi.org\/10.1021\/acs.chemrev.2c00431","journal-title":"Chem Rev"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","volume":"44","author":"VTE Aho","year":"2019","unstructured":"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, Scheperjans F (2019) Gut microbiota in Parkinson\u2019s disease: temporal stability and relations to disease progression. eBioMedicine 44:691\u2013707. https:\/\/doi.org\/10.1016\/j.ebiom.2019.05.064","journal-title":"eBioMedicine"},{"key":"2462_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fufo.2025.100680","volume":"12","author":"S Ali","year":"2025","unstructured":"Ali S, Hamayun M, Siraj M, Khan SA, Kim H-Y, Lee B (2025) Recent advances in prebiotics: classification, mechanisms, and health applications. Future Foods 12:100680. https:\/\/doi.org\/10.1016\/j.fufo.2025.100680","journal-title":"Future Foods"},{"issue":"2","key":"2462_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00702-023-02696-5","volume":"131","author":"M Al-Wardat","year":"2024","unstructured":"Al-Wardat M, Grillo P, Schirinzi T, Pavese C, Salimei C, Pisani A, Natoli S (2024) Constipation and pain in Parkinson\u2019s disease: a clinical analysis. J Neural Transm 131(2):165\u2013172. https:\/\/doi.org\/10.1007\/s00702-023-02696-5","journal-title":"J Neural Transm"},{"key":"2462_CR8","doi-asserted-by":"publisher","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. In: Drug Discov Today 21(5):802\u2013818. Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","DOI":"10.1016\/j.drudis.2016.01.013"},{"issue":"10103","key":"2462_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. The Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"The Lancet"},{"key":"2462_CR10","doi-asserted-by":"publisher","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T (2019) Post hoc analysis of the Exenatide-PD trial\u2014Factors that predict response.\u00a0Eur J NeuroSci 49(3):410\u2013421. https:\/\/doi.org\/10.1111\/ejn.14096","DOI":"10.1111\/ejn.14096"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-021-00215-5","volume":"7","author":"F Baert","year":"2021","unstructured":"Baert F, Matthys C, Maselyne J, Van Poucke C, Van Coillie E, Bergmans B, Vlaemynck G (2021) Parkinson\u2019s disease patients\u2019 short chain fatty acids production capacity after in vitro fecal fiber fermentation. NPJ Parkinsons Dis 7:72. https:\/\/doi.org\/10.1038\/s41531-021-00215-5","journal-title":"NPJ Parkinsons Dis"},{"key":"2462_CR12","doi-asserted-by":"publisher","unstructured":"Bhattacharyya D, Mohite GM, Krishnamoorthy J, Gayen N, Mehra S, Navalkar A, Kotler SA, Ratha BN, Ghosh A, Kumar R, Garai K, Mandal AK, Maji SK, Bhunia A (2019) Lipopolysaccharide from gut microbiota modulates \u03b1-Synuclein aggregation and alters its biological function. ACS Chem Neurosci 10(5):2229\u20132236. https:\/\/doi.org\/10.1021\/acschemneuro.8b00733","DOI":"10.1021\/acschemneuro.8b00733"},{"issue":"5","key":"2462_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, R\u00fcb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110(5):517\u2013536. https:\/\/doi.org\/10.1007\/s00702-002-0808-2","journal-title":"J Neural Transm"},{"key":"2462_CR14","doi-asserted-by":"publisher","unstructured":"Brown GC, Camacho M, Williams-Gray CH (2023) The endotoxin hypothesis of Parkinson\u2019s disease. In: Mov Disord 38(7):1143\u20131155. John Wiley and Sons Inc. https:\/\/doi.org\/10.1002\/mds.29432","DOI":"10.1002\/mds.29432"},{"key":"2462_CR15","doi-asserted-by":"publisher","first-page":"1617106","DOI":"10.3389\/fngai.2025.1617106","volume":"17","author":"SA Chaudhary","year":"2025","unstructured":"Chaudhary SA, Chaudhary S, Rawat S (2025) Understanding Parkinson\u2019s disease: current trends and its multifaceted complications. Front Aging Neurosci 17:1617106. https:\/\/doi.org\/10.3389\/fngai.2025.1617106","journal-title":"Front Aging Neurosci"},{"key":"2462_CR16","doi-asserted-by":"publisher","first-page":"106870","DOI":"10.1016\/j.jff.2025.106870","volume":"129","author":"U Choe","year":"2025","unstructured":"Choe U (2025) Role of dietary fiber and short-chain fatty acids in preventing neurodegenerative diseases through the gut-brain axis. J Funct Foods 129:106870. https:\/\/doi.org\/10.1016\/j.jff.2025.106870","journal-title":"J Funct Foods"},{"key":"2462_CR17","doi-asserted-by":"publisher","first-page":"1268419","DOI":"10.3389\/fnins.2023.1268419","volume":"17","author":"CR Denman","year":"2023","unstructured":"Denman CR, Park SM, Jo J (2023) Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer\u2019s and Parkinson\u2019s disease. Front Neurosci 17:1268419. https:\/\/doi.org\/10.3389\/fnins.2023.1268419","journal-title":"Front Neurosci"},{"issue":"2","key":"2462_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","volume":"19","author":"F Di Vincenzo","year":"2024","unstructured":"Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F (2024) Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 19(2):275\u2013293. https:\/\/doi.org\/10.1007\/s11739-023-03374-w","journal-title":"Intern Emerg Med"},{"issue":"21","key":"2462_CR19","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.3390\/ijms232113043","volume":"23","author":"LP Dolgacheva","year":"2022","unstructured":"Dolgacheva LP, Zinchenko VP, Goncharov NV (2022) Molecular and cellular interactions in pathogenesis of sporadic Parkinson disease. Int J Mol Sci 23(21):13043. https:\/\/doi.org\/10.3390\/ijms232113043","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2462_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12264-023-01123-9","volume":"40","author":"W-X Duan","year":"2023","unstructured":"Duan W-X, Wang F, Liu J-Y, Liu C-F (2023) Relationship between short-chain fatty acids and Parkinson\u2019s disease: a review from pathology to clinic. Neurosci Bull 40(4):500\u2013516. https:\/\/doi.org\/10.1007\/s12264-023-01123-9","journal-title":"Neurosci Bull"},{"issue":"5","key":"2462_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/life14050559","volume":"14","author":"S Facchin","year":"2024","unstructured":"Facchin S, Bertin L, Bonazzi E, Lorenzon G, De Barba C, Barberio B, Zingone F, Maniero D, Scarpa M, Ruffolo C, Angriman I, Savarino EV (2024) Short-chain fatty acids and human health: from metabolic pathways to current therapeutic implications. Life 14(5):559. https:\/\/doi.org\/10.3390\/life14050559","journal-title":"Life"},{"issue":"1","key":"2462_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02393-8","volume":"23","author":"X Fan","year":"2025","unstructured":"Fan X, Xiao Z, Chen Y, Yang H, Diao M, Hu W, Wang S (2025) Interactions between gut microbiota and parkinson\u2019s disease: the role of tryptophan metabolism. Cell Commun Signal 23(1):424. https:\/\/doi.org\/10.1186\/s12964-025-02393-8","journal-title":"Cell Commun Signal"},{"issue":"9","key":"2462_CR23","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.4103\/1673-5374.391191","volume":"19","author":"X Fang","year":"2024","unstructured":"Fang X, Liu S, Muhammad B, Zheng M, Ge X, Xu Y, Kan S, Zhang Y, Yu Y, Zheng K, Geng D, Liu C-F (2024) Gut microbiota dysbiosis contributes to \u03b1-synuclein-related pathology associated with C\/EBP\u03b2\/AEP signaling activation in a mouse model of Parkinson\u2019s disease. Neural Regen Res 19(9):2081\u20132088. https:\/\/doi.org\/10.4103\/1673-5374.391191","journal-title":"Neural Regen Res"},{"issue":"2","key":"2462_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12020325","volume":"12","author":"J Forero-Rodr\u00edguez","year":"2024","unstructured":"Forero-Rodr\u00edguez J, Zimmermann J, Taubenheim J, Arias-Rodr\u00edguez N, Caicedo-Narvaez JD, Best L, Mendieta CV, L\u00f3pez-Castiblanco J, G\u00f3mez-Mu\u00f1oz LA, Gonzalez-Santos J, Arboleda H, Fernandez W, Kaleta C, Pinz\u00f3n A (2024) Changes in bacterial gut composition in Parkinson\u2019s disease and their metabolic contribution to disease development: a gut community reconstruction approach. Microorganisms 12(2):325. https:\/\/doi.org\/10.3390\/microorganisms12020325","journal-title":"Microorganisms"},{"issue":"2","key":"2462_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15020159","volume":"15","author":"A Gao","year":"2025","unstructured":"Gao A, Lv J, Su Y (2025) The inflammatory mechanism of Parkinson\u2019s disease: gut microbiota metabolites affect the development of the disease through the gut\u2013brain axis. Brain Sci 15(2):2. https:\/\/doi.org\/10.3390\/brainsci15020159","journal-title":"Brain Sci"},{"issue":"1","key":"2462_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 8(1):1\u201337. https:\/\/doi.org\/10.1038\/s41392-023-01588-0","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2462_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13847","volume":"52","author":"E Garc\u00eda-Mart\u00edn","year":"2022","unstructured":"Garc\u00eda-Mart\u00edn E, Pastor P, G\u00f3mez-Tabales J, Alonso-Navarro H, Alvarez I, Buongiorno M, de las Olas Cerezo-Arias M, Aguilar M, Ag\u00fandez JAG, Jim\u00e9nez-Jim\u00e9nez FJ (2022) Association between LAG3\/CD4 gene variants and risk of Parkinson\u2019s disease. Eur J Clin Invest 52(11):e13847. https:\/\/doi.org\/10.1111\/eci.13847","journal-title":"Eur J Clin Invest"},{"key":"2462_CR28","doi-asserted-by":"publisher","unstructured":"Hall DA, Voigt RM, Cantu-Jungles TM, Hamaker B, Engen PA, Shaikh M, Raeisi S, Green SJ, Naqib A, Forsyth CB, Chen T, Manfready R, Ouyang B, Rasmussen HE, Sedghi S, Goetz CG, Keshavarzian A (2023) An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson\u2019s disease participants.\u00a0Nat Commun 14(1). https:\/\/doi.org\/10.1038\/s41467-023-36497-x","DOI":"10.1038\/s41467-023-36497-x"},{"issue":"6","key":"2462_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00462","volume":"21","author":"AM Hamilton","year":"2024","unstructured":"Hamilton AM, Krout IN, White AC, Sampson TR (2024) Microbiome-based therapeutics for Parkinson\u2019s disease. Neurotherapeutics 21(6):e00462. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00462","journal-title":"Neurotherapeutics"},{"key":"2462_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1237177","volume":"17","author":"SS Hayer","year":"2023","unstructured":"Hayer SS, Hwang S, Clayton JB (2023) Antibiotic-induced gut dysbiosis and cognitive, emotional, and behavioral changes in rodents: a systematic review and meta-analysis. Front Neurosci 17:1237177. https:\/\/doi.org\/10.3389\/fnins.2023.1237177","journal-title":"Front Neurosci"},{"key":"2462_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1158986","volume":"13","author":"AS Higinbotham","year":"2024","unstructured":"Higinbotham AS, Kilbane CW (2024) The gastrointestinal tract and Parkinson\u2019s disease. Front Cell Infect Microbiol 13:1158986. https:\/\/doi.org\/10.3389\/fcimb.2023.1158986","journal-title":"Front Cell Infect Microbiol"},{"key":"2462_CR32","doi-asserted-by":"publisher","unstructured":"Hirayama M, Nishiwaki H, Hamaguchi T, et al (2023) Gastrointestinal disorders in Parkinson\u2019s disease and other Lewy body diseases. npj Parkinsons Dis 9:71. https:\/\/doi.org\/10.1038\/s41531-023-00511-2","DOI":"10.1038\/s41531-023-00511-2"},{"issue":"4","key":"2462_CR33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1440-1746.2009.05780.x","volume":"24","author":"T Hiyama","year":"2009","unstructured":"Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K (2009) Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol 24(4):537\u2013546. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05780.x","journal-title":"J Gastroenterol Hepatol"},{"key":"2462_CR34","doi-asserted-by":"publisher","unstructured":"H\u00f6lscher C (2014) The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer\u2019s disease. In: Alzheimer\u2019s and Dementia (Vol. 10, Issue 1 SUPPL.). Elsevier Inc. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.009","DOI":"10.1016\/j.jalz.2013.12.009"},{"key":"2462_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109952","volume":"253","author":"C H\u00f6lscher","year":"2024","unstructured":"H\u00f6lscher C (2024) Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: a revolution in the making? Neuropharmacology 253:109952. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109952","journal-title":"Neuropharmacology"},{"issue":"21","key":"2462_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213468","volume":"11","author":"C-T Hong","year":"2022","unstructured":"Hong C-T, Chan L, Chen K-Y, Lee H-H, Huang L-K, Yang Y-CSH, Liu Y-R, Hu C-J (2022) Rifaximin modifies gut microbiota and attenuates inflammation in Parkinson\u2019s disease: preclinical and clinical studies. Cells 11(21):3468. https:\/\/doi.org\/10.3390\/cells11213468","journal-title":"Cells"},{"key":"2462_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115735","volume":"168","author":"Q Huang","year":"2023","unstructured":"Huang Q, Yang P, Liu Y, Ding J, Lu M, Hu G (2023) The interplay between \u03b1-Synuclein and NLRP3 inflammasome in Parkinson\u2019s disease. Biomed Pharmacother 168:115735. https:\/\/doi.org\/10.1016\/j.biopha.2023.115735","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2462_CR38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47861","volume":"15","author":"A Jain","year":"2023","unstructured":"Jain A, Madkan S, Patil P (2023) The role of gut microbiota in neurodegenerative diseases: current insights and therapeutic implications. Cureus 15(10):e47861. https:\/\/doi.org\/10.7759\/cureus.47861","journal-title":"Cureus"},{"issue":"7","key":"2462_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073812","volume":"25","author":"K Kalinderi","year":"2024","unstructured":"Kalinderi K, Papaliagkas V, Fidani L (2024) GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease. Int J Mol Sci 25(7):3812. https:\/\/doi.org\/10.3390\/ijms25073812","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2462_CR40","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26307","volume":"30","author":"A Keshavarzian","year":"2015","unstructured":"Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM (2015) Colonic bacterial composition in Parkinson\u2019s disease. Mov Disord 30(10):1351\u20131360. https:\/\/doi.org\/10.1002\/mds.26307","journal-title":"Mov Disord"},{"key":"2462_CR41","doi-asserted-by":"publisher","unstructured":"Kiani AK, Anpilogov K, Dautaj A, Marceddu G, Sonna WN, Percio M, Dundar M, Beccari T, Bertelli, M (2020) Bacteriophages in food supplements obtained from natural sources. In Acta Biomedica (Vol. 91, pp. 1\u20136). Mattioli 1885. https:\/\/doi.org\/10.23750\/abm.v91i13-S.10834","DOI":"10.23750\/abm.v91i13-S.10834"},{"issue":"1","key":"2462_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.engmic.2025.100189","volume":"5","author":"X Kuang","year":"2025","unstructured":"Kuang X, Shen J, Zheng L, Duan Y, Ma Y, Leung EL-H, Dai L (2025) Applications of bacteriophages in precision engineering of the human gut microbiome. Eng Microbiol 5(1):100189. https:\/\/doi.org\/10.1016\/j.engmic.2025.100189","journal-title":"Eng Microbiol"},{"issue":"8","key":"2462_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083658","volume":"26","author":"N Kurhaluk","year":"2025","unstructured":"Kurhaluk N, Kami\u0144ski P, Bilski R, Ko\u0142odziejska R, Wo\u017aniak A, Tkaczenko H (2025) Role of antioxidants in modulating the microbiota\u2013gut\u2013brain axis and their impact on neurodegenerative diseases. Int J Mol Sci 26(8):8. https:\/\/doi.org\/10.3390\/ijms26083658","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2462_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14411","volume":"30","author":"H Li","year":"2024","unstructured":"Li H, Zeng F, Huang C, Pu Q, Thomas ER, Chen Y, Li X (2024) The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson\u2019s disease. CNS Neurosci Ther 30(2):e14411. https:\/\/doi.org\/10.1111\/cns.14411","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"2462_CR45","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s11427-016-9001-4","volume":"60","author":"W Li","year":"2017","unstructured":"Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B (2017) Structural changes of gut microbiota in Parkinson\u2019s disease and its correlation with clinical features. Sci China Life Sci 60(11):1223\u20131233. https:\/\/doi.org\/10.1007\/s11427-016-9001-4","journal-title":"Sci China Life Sci"},{"key":"2462_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719807","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Xia Y, Yin S, Wan F, Hu J, Kou L, Sun Y, Wu J, Zhou Q, Huang J, Xiong N, Wang T (2021) Targeting microglial \u03b1-Synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson\u2019s disease. Front Immunol 12:719807. https:\/\/doi.org\/10.3389\/fimmu.2021.719807","journal-title":"Front Immunol"},{"issue":"8","key":"2462_CR47","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1007\/s12035-021-02375-0","volume":"58","author":"Y Liang","year":"2021","unstructured":"Liang Y, Cui L, Gao J, Zhu M, Zhang Y, Zhang H-L (2021) Gut microbial metabolites in Parkinson\u2019s disease: implications of mitochondrial dysfunction in the pathogenesis and treatment. Mol Neurobiol 58(8):3745\u20133758. https:\/\/doi.org\/10.1007\/s12035-021-02375-0","journal-title":"Mol Neurobiol"},{"key":"2462_CR48","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.2147\/JIR.S539155","volume":"18","author":"L Lin","year":"2025","unstructured":"Lin L, George J, Liu G (2025) Biomarker quantification of gut dysbiosis-derived inflammation: a review. J Inflamm Res 18:14551\u201314567. https:\/\/doi.org\/10.2147\/JIR.S539155","journal-title":"J Inflamm Res"},{"key":"2462_CR49","doi-asserted-by":"publisher","unstructured":"Liu T, Wu H, Wei J (2025a) Beyond the brain: exploring the multi-organ axes in Parkinson\u2019s disease pathogenesis.\u00a0J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2025.05.034","DOI":"10.1016\/j.jare.2025.05.034"},{"key":"2462_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1556827","author":"Y Liu","year":"2025","unstructured":"Liu Y, Li X, Chen Y, Yao Q, Zhou J, Wang X, Meng Q, Ji J, Yu Z, Chen X (2025b) Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2025.1556827","journal-title":"Front Microbiol"},{"key":"2462_CR51","doi-asserted-by":"publisher","unstructured":"Loh JS, Mak WQ, Tan LKS, et al (2024) Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases. Sig Transduct Target Ther 9:37. https:\/\/doi.org\/10.1038\/s41392-024-01743-1","DOI":"10.1038\/s41392-024-01743-1"},{"key":"2462_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2025.111609","volume":"198","author":"X-M Luo","year":"2025","unstructured":"Luo X-M, Luo J, Zeng L-Y, Chi C-L (2025) Gut microbiota as a potential mechanism besides ketone bodies in ameliorating Parkinson\u2019s disease symptoms with the ketogenic diet. Med Hypotheses 198:111609. https:\/\/doi.org\/10.1016\/j.mehy.2025.111609","journal-title":"Med Hypotheses"},{"key":"2462_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.focha.2025.100919","volume":"6","author":"AN Mafe","year":"2025","unstructured":"Mafe AN, Edo GI, Majeed OS, Gaaz TS, Akpoghelie PO, Isoje EF, Igbuku UA, Owheruo JO, Opiti RA, Garba Y, Essaghah AEA, Ahmed DS, Umar H (2025) A review on probiotics and dietary bioactives: insights on metabolic well-being, gut microbiota, and inflammatory responses. Food Chemistry Advances 6:100919. https:\/\/doi.org\/10.1016\/j.focha.2025.100919","journal-title":"Food Chemistry Advances"},{"issue":"1","key":"2462_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49016-3","volume":"15","author":"X Mao","year":"2024","unstructured":"Mao X, Gu H, Kim D, Kimura Y, Wang N, Xu E, Kumbhar R, Ming X, Wang H, Chen C, Zhang S, Jia C, Liu Y, Bian H, Karuppagounder SS, Akkentli F, Chen Q, Jia L, Hwang H et al (2024) Aplp1 interacts with Lag3 to facilitate transmission of pathologic \u03b1-synuclein. Nat Commun 15(1):4663. https:\/\/doi.org\/10.1038\/s41467-024-49016-3","journal-title":"Nat Commun"},{"issue":"6307","key":"2462_CR55","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gon\u00e7alves RA, Liang Y et al (2016) Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, NY) 353(6307):aah3374. https:\/\/doi.org\/10.1126\/science.aah3374","journal-title":"Science (New York, NY)"},{"key":"2462_CR56","doi-asserted-by":"publisher","unstructured":"Martin AM, Sun EW, Keating DJ (2019) Mechanisms controlling hormone secretion in human gut and its relevance to metabolism. J Endocrinol 244(1):R1\u2013R15. https:\/\/doi.org\/10.1530\/JOE-19-0399","DOI":"10.1530\/JOE-19-0399"},{"issue":"4","key":"2462_CR57","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.14644","volume":"28","author":"M Melis","year":"2021","unstructured":"Melis M, Vascellari S, Santoru ML, Oppo V, Fabbri M, Sarchioto M, Murgia D, Zibetti M, Lopiano L, Serra A, Palmas V, Pisanu S, Perra D, Madau V, Cusano R, Uva P, Mereu A, Contu P, Morelli M et al (2021) Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur J Neurol 28(4):1198\u20131209. https:\/\/doi.org\/10.1111\/ene.14644","journal-title":"Eur J Neurol"},{"issue":"1","key":"2462_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/14796708.2025.2494981","volume":"20","author":"A Metcalfe-Roach","year":"2025","unstructured":"Metcalfe-Roach A, Finlay BB (2025) The role of the gut microbiome in Parkinson\u2019s disease. Future Neurol 20(1):2494981. https:\/\/doi.org\/10.1080\/14796708.2025.2494981","journal-title":"Future Neurol"},{"key":"2462_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106889","volume":"209","author":"YB Mingo","year":"2025","unstructured":"Mingo YB, Escobar Galvis ML, Henderson MX (2025) \u0391-Synuclein pathology and mitochondrial dysfunction: toxic partners in Parkinson\u2019s disease. Neurobiol Dis 209:106889. https:\/\/doi.org\/10.1016\/j.nbd.2025.106889","journal-title":"Neurobiol Dis"},{"issue":"4","key":"2462_CR60","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/s0306-4522(96)00655-0","volume":"78","author":"AF Miranda","year":"1997","unstructured":"Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K (1997) Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78(4):967\u2013975. https:\/\/doi.org\/10.1016\/s0306-4522(96)00655-0","journal-title":"Neuroscience"},{"key":"2462_CR61","doi-asserted-by":"publisher","unstructured":"Mulak A, Bonaz B (2015) Brain-gut-microbiota axis in Parkinson\u2019s disease. In:\u00a0World J Gastroenterol 21(37):10609\u201310620. WJG Press. https:\/\/doi.org\/10.3748\/wjg.v21.i37.10609","DOI":"10.3748\/wjg.v21.i37.10609"},{"key":"2462_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2025.1590002","volume":"19","author":"L M\u00fcller","year":"2025","unstructured":"M\u00fcller L, Di Benedetto S (2025) Bridging the brain and gut: Neuroimmune mechanisms of neuroinflammation and therapeutic insights. Front Cell Neurosci 19:1590002. https:\/\/doi.org\/10.3389\/fncel.2025.1590002","journal-title":"Front Cell Neurosci"},{"key":"2462_CR63","doi-asserted-by":"publisher","unstructured":"Munoz-Pinto MF, Candeias E, Melo-Marques I, et al (2024) Gut-first Parkinson\u2019s disease is encoded by gut dysbiome. Mol Neurodegeneration 19:78. https:\/\/doi.org\/10.1186\/s13024-024-00766-0","DOI":"10.1186\/s13024-024-00766-0"},{"issue":"4","key":"2462_CR64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/WNF.0b013e3182575cdb","volume":"35","author":"N Nishikawa","year":"2012","unstructured":"Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M (2012) Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 35(4):182\u2013184. https:\/\/doi.org\/10.1097\/WNF.0b013e3182575cdb","journal-title":"Clin Neuropharmacol"},{"key":"2462_CR65","doi-asserted-by":"publisher","unstructured":"Nishiwaki H, Hamaguchi T, Ito M, Ishida T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Shimamura T, Mori H, Kurokawa K, Katsuno M, Hirayama M, Ohno K (2020) Short-chain fatty acid-producing gut microbiota is decreased in Parkinson's Disease but not in rapid-eye-movement sleep behavior disorder. mSystems 5(6):e00797-20. https:\/\/doi.org\/10.1128\/mSystems.00797-20","DOI":"10.1128\/mSystems.00797-20"},{"issue":"1","key":"2462_CR66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/epi-2023-0342","volume":"16","author":"S Nohesara","year":"2024","unstructured":"Nohesara S, Abdolmaleky HM, Thiagalingam S, Zhou J-R (2024) Gut microbiota defined epigenomes of Alzheimer\u2019s and Parkinson\u2019s diseases reveal novel targets for therapy. Epigenomics 16(1):57\u201377. https:\/\/doi.org\/10.2217\/epi-2023-0342","journal-title":"Epigenomics"},{"issue":"6","key":"2462_CR67","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00415-025-13138-5","volume":"272","author":"PJ Oliver","year":"2025","unstructured":"Oliver PJ, Civitelli L, Hu MT (2025) The gut\u2013brain axis in early Parkinson\u2019s disease: from prodrome to prevention. J Neurol 272(6):413. https:\/\/doi.org\/10.1007\/s00415-025-13138-5","journal-title":"J Neurol"},{"key":"2462_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1307447","volume":"14","author":"NA Omar","year":"2023","unstructured":"Omar NA, Kumar J, Teoh SL (2023) Neuroprotective effects of Neurotrophin-3 in MPTP-induced zebrafish Parkinson\u2019s disease model. Front Pharmacol 14:1307447. https:\/\/doi.org\/10.3389\/fphar.2023.1307447","journal-title":"Front Pharmacol"},{"issue":"3","key":"2462_CR69","doi-asserted-by":"publisher","first-page":"938","DOI":"10.4103\/NRR.NRR-D-24-01265","volume":"21","author":"S Pang","year":"2026","unstructured":"Pang S, Ren Z, Ding H, Chan P (2026) Short-chain fatty acids mediate enteric and central nervous system homeostasis in Parkinson\u2019s disease: innovative therapies and their translation. Neural Regen Res 21(3):938. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-01265","journal-title":"Neural Regen Res"},{"key":"2462_CR70","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.4103\/jod.jod_103_23","volume":"14","author":"RM Parikh","year":"2023","unstructured":"Parikh RM, Saboo B, Mohan V, Basit A, Gupta A, Panda JK, Bhartia M, Topsever P (2023) Glucagon in the gut \u2013 brain axis. J Diabetol 14:S42. https:\/\/doi.org\/10.4103\/jod.jod_103_23","journal-title":"J Diabetol"},{"key":"2462_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-023-00536-1","volume":"15","author":"JM Park","year":"2023","unstructured":"Park JM, Lee SC, Ham C, Kim YW (2023) Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Gut Pathog 15:9. https:\/\/doi.org\/10.1186\/s13099-023-00536-1","journal-title":"Gut Pathog"},{"issue":"5","key":"2462_CR72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","volume":"68","author":"P Perez-Pardo","year":"2019","unstructured":"Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, Voigt RM, Naqib A, Green SJ, Kordower JH, Shannon KM, Garssen J, Kraneveld AD, Keshavarzian A (2019) Role of TLR4 in the gut-brain axis in Parkinson\u2019s disease: a translational study from men to mice. Gut 68(5):829\u2013843. https:\/\/doi.org\/10.1136\/gutjnl-2018-316844","journal-title":"Gut"},{"key":"2462_CR73","doi-asserted-by":"publisher","unstructured":"Peters M, Hegelmaier T, Wegner F, H\u00f6llerhage M, Ye L, Niesmann C, Schneidereit IV, Haghikia A, Klietz M (2025) The role of the gut microbiome in the progression of Parkinson's disease: a systematic review of patient cohorts. J Neurol 273(1):8. https:\/\/doi.org\/10.1007\/s00415-025-13545-8","DOI":"10.1007\/s00415-025-13545-8"},{"issue":"4","key":"2462_CR74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, Group the CS","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, Group the CS (2002) Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245\u2013255. https:\/\/doi.org\/10.1034\/j.1600-0404.2002.1o174.x","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2462_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00296-w","volume":"8","author":"S Rahimpour","year":"2022","unstructured":"Rahimpour S, Zhang S-C, Vitek JL, Mitchell KT, Turner DA (2022) Comparative efficacy of surgical approaches to disease modification in Parkinson disease. NPJ Parkinsons Dis 8(1):33. https:\/\/doi.org\/10.1038\/s41531-022-00296-w","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"2462_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-025-01609-2","volume":"45","author":"A Ravi","year":"2025","unstructured":"Ravi A, Umapathy S, Pan I (2025) Short-chain fatty acids as a therapeutic strategy in Parkinson\u2019s disease: implications for neurodegeneration. Cell Mol Neurobiol 45(1):90. https:\/\/doi.org\/10.1007\/s10571-025-01609-2","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"2462_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/nu16132041","volume":"16","author":"E Riegelman","year":"2024","unstructured":"Riegelman E, Xue KS, Wang J-S, Tang L (2024) Gut-brain axis in focus: polyphenols, microbiota, and their influence on \u03b1-Synuclein in Parkinson\u2019s disease. Nutrients 16(13):2041. https:\/\/doi.org\/10.3390\/nu16132041","journal-title":"Nutrients"},{"issue":"6","key":"2462_CR78","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s Disease. Cell 167(6):1469-1480.e12. https:\/\/doi.org\/10.1016\/j.cell.2016.11.018","journal-title":"Cell"},{"key":"2462_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00804-5","volume":"20","author":"TR Sampson","year":"2025","unstructured":"Sampson TR, Tansey MG, West AB, Liddle RA (2025) Lewy body diseases and the gut. Mol Neurodegener 20:14. https:\/\/doi.org\/10.1186\/s13024-025-00804-5","journal-title":"Mol Neurodegener"},{"issue":"3","key":"2462_CR80","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disor 30(3):350\u2013358. https:\/\/doi.org\/10.1002\/mds.26069","journal-title":"Mov Disor"},{"issue":"14","key":"2462_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/nu17142286","volume":"17","author":"RMUS Senarath","year":"2025","unstructured":"Senarath RMUS, Oikari LE, Bharadwaj P, Jayasena V, Martins RN, Fernando WMADB (2025) The therapeutic potential of butyrate and Lauric acid in modulating glial and neuronal activity in Alzheimer\u2019s disease. Nutrients 17(14):14. https:\/\/doi.org\/10.3390\/nu17142286","journal-title":"Nutrients"},{"key":"2462_CR82","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003508","volume-title":"Parkinson disease and the gut: a primer for gastroenterologists","author":"A Sharma","year":"2025","unstructured":"Sharma A, Voigt RM, Goetz CG, Keshavarzian A (2025) Parkinson disease and the gut: a primer for gastroenterologists. Official Journal of the American College of Gastroenterology | ACG. https:\/\/doi.org\/10.14309\/ajg.0000000000003508"},{"key":"2462_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1341950","author":"N Shebl","year":"2024","unstructured":"Shebl N, El-Jaafary S, Saeed AA, Elkafrawy P, El-Sayed A, Shamma S, Elnemr R, Mekky J, Mohamed LA, Kittaneh O, El-Fawal H, Rizig M, Salama M (2024) Metabolomic profiling reveals altered phenylalanine metabolism in Parkinson\u2019s disease in an Egyptian cohort. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2024.1341950","journal-title":"Front Mol Biosci"},{"issue":"4","key":"2462_CR84","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, S\u00f8rensen HT (2015) Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann Neurol 78(4):522\u2013529. https:\/\/doi.org\/10.1002\/ana.24448","journal-title":"Ann Neurol"},{"key":"2462_CR85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.parkreldis.2021.12.012","volume":"95","author":"K Takahashi","year":"2022","unstructured":"Takahashi K, Nishiwaki H, Ito M, Iwaoka K, Takahashi K, Suzuki Y, Taguchi K, Yamahara K, Tsuboi Y, Kashihara K, Hirayama M, Ohno K, Maeda T (2022) Altered gut microbiota in Parkinson\u2019s disease patients with motor complications. Parkinsonism Relat Disord 95:11\u201317. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.12.012","journal-title":"Parkinsonism Relat Disord"},{"key":"2462_CR86","doi-asserted-by":"publisher","unstructured":"Terry N, Margolis KG (2017) Serotonergic mechanisms regulating the GI tract: experimental evidence and therapeutic relevance.\u00a0Handb Exp Pharmacol 239:319\u2013342. https:\/\/doi.org\/10.1007\/164_2016_103","DOI":"10.1007\/164_2016_103"},{"key":"2462_CR87","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger MM, Spiegel J, Dillmann K-U, Grundmann D, Philippeit H, B\u00fcrmann J, Fa\u00dfbender K, Schwiertz A, Sch\u00e4fer K-H (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat Disord 32:66\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.08.019","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2462_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.01191-21","volume":"7","author":"SP van Kessel","year":"2022","unstructured":"van Kessel SP, Bullock A, van Dijk G, El Aidy S (2022) Parkinson\u2019s disease medication alters small intestinal motility and microbiota composition in healthy rats. mSystems 7(1):e0119121. https:\/\/doi.org\/10.1128\/msystems.01191-21","journal-title":"mSystems"},{"issue":"16","key":"2462_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/nu16162646","volume":"16","author":"SM van Zonneveld","year":"2024","unstructured":"van Zonneveld SM, van den Oever EJ, Haarman BCM, Grandjean EL, Nuninga JO, van de Rest O, Sommer IEC (2024) An anti-inflammatory diet and its potential benefit for individuals with mental disorders and neurodegenerative diseases-a narrative review. Nutrients 16(16):2646. https:\/\/doi.org\/10.3390\/nu16162646","journal-title":"Nutrients"},{"issue":"1","key":"2462_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34667-x","volume":"13","author":"ZD Wallen","year":"2022","unstructured":"Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR, Payami H (2022) Metagenomics of Parkinson\u2019s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun 13(1):6958. https:\/\/doi.org\/10.1038\/s41467-022-34667-x","journal-title":"Nat Commun"},{"key":"2462_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656165","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Li Y, Xia Y (2025a) C\/EBP\u03b2 as a master regulator of inflammasome signaling in neurodegenerative diseases: mechanisms and therapeutic implications. Front Immunol 16:1656165. https:\/\/doi.org\/10.3389\/fimmu.2025.1656165","journal-title":"Front Immunol"},{"issue":"3","key":"2462_CR92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/CM9.0000000000003318","volume":"138","author":"L Wang","year":"2025","unstructured":"Wang L, Cui Y, Han B, Du Y, Salewala KS, Wang S, Zhao W, Zhang H, Wang S, Xu X, Ma J, Zhu Y, Tuo H (2025b) Gut microbiota and Parkinson\u2019s disease. Chin Med J 138(3):289\u2013297","journal-title":"Chin Med J"},{"key":"2462_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00691-5","volume":"10","author":"Z Wang","year":"2024","unstructured":"Wang Z, Ma D, Li M, Liang Y, Hu Z, Li S, Zuo C, Hao C, Feng Y, Guo M, Hao X, Guo Y, Ma K, Guo L, Zhang C, Xu Y, Mao C, Shi C (2024) Association between irritable bowel syndrome and Parkinson\u2019s disease by cohort study and Mendelian randomization analysis. NPJ Parkinsons Dis 10:70. https:\/\/doi.org\/10.1038\/s41531-024-00691-5","journal-title":"NPJ Parkinsons Dis"},{"key":"2462_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00295-x","volume":"8","author":"T Warnecke","year":"2022","unstructured":"Warnecke T, Sch\u00e4fer K-H, Claus I, Tredici KD, Jost WH (2022) Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 8:31. https:\/\/doi.org\/10.1038\/s41531-022-00295-x","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"2462_CR95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.chom.2014.09.001","volume":"16","author":"BB Williams","year":"2014","unstructured":"Williams BB, Van Benschoten AH, Cimermancic P, Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA (2014) Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16(4):495\u2013503. https:\/\/doi.org\/10.1016\/j.chom.2014.09.001","journal-title":"Cell Host Microbe"},{"issue":"2","key":"2462_CR96","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41380-020-0687-7","volume":"26","author":"Z Wu","year":"2021","unstructured":"Wu Z, Xia Y, Wang Z, Su Kang S, Lei K, Liu X, Jin L, Wang X, Cheng L, Ye K (2021) C\/EBP\u03b2\/\u03b4-secretase signaling mediates Parkinson\u2019s disease pathogenesis via regulating transcription and proteolytic cleavage of \u03b1-synuclein and MAOB. Mol Psychiatry 26(2):568\u2013585. https:\/\/doi.org\/10.1038\/s41380-020-0687-7","journal-title":"Mol Psychiatry"},{"key":"2462_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1007654","volume":"13","author":"L Xie","year":"2023","unstructured":"Xie L, Chen D, Zhu X, Cheng C (2023) Efficacy and safety of probiotics in Parkinson\u2019s constipation: a systematic review and meta-analysis. Front Pharmacol 13:1007654. https:\/\/doi.org\/10.3389\/fphar.2022.1007654","journal-title":"Front Pharmacol"},{"key":"2462_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1468850","volume":"15","author":"K Yang","year":"2024","unstructured":"Yang K, Lv Z, Zhao W, Lai G, Zheng C, Qi F, Zhao C, Hu K, Chen X, Fu F, Li J, Xie G, Wang H, Wu X, Zheng W (2024) The potential of natural products to inhibit abnormal aggregation of \u03b1-Synuclein in the treatment of Parkinson\u2019s disease. Front Pharmacol 15:1468850. https:\/\/doi.org\/10.3389\/fphar.2024.1468850","journal-title":"Front Pharmacol"},{"key":"2462_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1224964","volume":"16","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Tian Y, Jiang H, Cai L-Y, Song J, Peng R, Zhang X-M (2023) <article-title update=\"added\">Mechanism of PGC-1\u03b1-mediated mitochondrial biogenesis in cerebral ischemia\u2013reperfusion injury. Front Mol Neurosci 16:1224964. https:\/\/doi.org\/10.3389\/fnmol.2023.1224964","journal-title":"Front Mol Neurosci"},{"issue":"23","key":"2462_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235698","volume":"10","author":"B Zapa\u0142a","year":"2021","unstructured":"Zapa\u0142a B, Stefura T, W\u00f3jcik-P\u0119dziwiatr M, Kabut R, Ba\u0142ajewicz-Nowak M, Milewicz T, Dudek A, St\u00f3j A, Rudzi\u0144ska-Bar M (2021) Differences in the composition of gut microbiota between patients with Parkinson\u2019s disease and healthy controls: a cohort study. J Clin Med 10(23):5698. https:\/\/doi.org\/10.3390\/jcm10235698","journal-title":"J Clin Med"},{"issue":"1","key":"2462_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-02065-z","volume":"18","author":"D Zhang","year":"2021","unstructured":"Zhang D, Li S, Hou L, Jing L, Ruan Z, Peng B, Zhang X, Hong J-S, Zhao J, Wang Q (2021) Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson\u2019s disease model. J Neuroinflammation 18(1):4. https:\/\/doi.org\/10.1186\/s12974-020-02065-z","journal-title":"J Neuroinflammation"},{"key":"2462_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107410","volume":"208","author":"L-Y Zhang","year":"2024","unstructured":"Zhang L-Y, Zhang S-Y, Wen R, Zhang T-N, Yang N (2024) Role of histone deacetylases and their inhibitors in neurological diseases. Pharmacol Res 208:107410. https:\/\/doi.org\/10.1016\/j.phrs.2024.107410","journal-title":"Pharmacol Res"},{"issue":"1","key":"2462_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00392-8","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Tang B, Guo J (2023) Parkinson\u2019s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Transl Neurodegener 12(1):59. https:\/\/doi.org\/10.1186\/s40035-023-00392-8","journal-title":"Transl Neurodegener"},{"issue":"1","key":"2462_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02043-4","volume":"10","author":"X Zhou","year":"2025","unstructured":"Zhou X, Wu Y, Zhu Z, Lu C, Zhang C, Zeng L, Xie F, Zhang L, Zhou F (2025) Mucosal immune response in biology, disease prevention and treatment. Signal Transduct Target Ther 10(1):7. https:\/\/doi.org\/10.1038\/s41392-024-02043-4","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-025-02462-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:42:53Z","timestamp":1774402973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-025-02462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1007\/s12031-025-02462-0","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}